Compare Orchid Chemicals with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs SUN PHARMA - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD SUN PHARMA ORCHID PHARMA LTD/
SUN PHARMA
 
P/E (TTM) x -0.5 21.3 - View Chart
P/BV x 0.1 2.5 4.7% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ORCHID PHARMA LTD   SUN PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
SUN PHARMA
Mar-19
ORCHID PHARMA LTD/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs194679 28.6%   
Low Rs35375 9.3%   
Sales per share (Unadj.) Rs276.5121.1 228.2%  
Earnings per share (Unadj.) Rs-79.213.4 -592.2%  
Cash flow per share (Unadj.) Rs-43.520.7 -210.1%  
Dividends per share (Unadj.) Rs02.75 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs53.9172.6 31.3%  
Shares outstanding (eoy) m70.452,399.26 2.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.44.4 9.5%   
Avg P/E ratio x-1.439.4 -3.7%  
P/CF ratio (eoy) x-2.625.5 -10.3%  
Price / Book Value ratio x2.13.1 69.5%  
Dividend payout %020.6 0.0%   
Avg Mkt Cap Rs m8,0671,264,650 0.6%   
No. of employees `0002.817.5 16.0%   
Total wages/salary Rs m2,52759,671 4.2%   
Avg. sales/employee Rs Th6,956.116,608.1 41.9%   
Avg. wages/employee Rs Th902.53,409.6 26.5%   
Avg. net profit/employee Rs Th-1,993.01,833.8 -108.7%   
INCOME DATA
Net Sales Rs m19,477290,659 6.7%  
Other income Rs m40710,255 4.0%   
Total revenues Rs m19,884300,914 6.6%   
Gross profit Rs m1,10363,076 1.7%  
Depreciation Rs m2,51917,533 14.4%   
Interest Rs m5,2275,553 94.1%   
Profit before tax Rs m-6,23650,246 -12.4%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511-12,144 -4.2%   
Tax Rs m-1256,009 -2.1%   
Profit after tax Rs m-5,58032,093 -17.4%  
Gross profit margin %5.721.7 26.1%  
Effective tax rate %2.012.0 16.8%   
Net profit margin %-28.711.0 -259.5%  
BALANCE SHEET DATA
Current assets Rs m11,014310,692 3.5%   
Current liabilities Rs m32,060173,396 18.5%   
Net working cap to sales %-108.147.2 -228.8%  
Current ratio x0.31.8 19.2%  
Inventory Days Days9599 95.8%  
Debtors Days Days34112 30.1%  
Net fixed assets Rs m29,440232,477 12.7%   
Share capital Rs m7052,399 29.4%   
"Free" reserves Rs m2,043411,691 0.5%   
Net worth Rs m3,800414,091 0.9%   
Long term debt Rs m9,01815,226 59.2%   
Total assets Rs m46,510646,938 7.2%  
Interest coverage x-0.210.0 -1.9%   
Debt to equity ratio x2.40 6,454.2%  
Sales to assets ratio x0.40.4 93.2%   
Return on assets %-0.85.8 -13.1%  
Return on equity %-146.97.8 -1,894.8%  
Return on capital %-3.710.2 -36.7%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51366,025 11.4%   
Fx outflow Rs m5,64938,610 14.6%   
Net fx Rs m1,86527,415 6.8%   
CASH FLOW
From Operations Rs m1,68221,965 7.7%  
From Investments Rs m-9,860-6,813 144.7%  
From Financial Activity Rs m6,644-27,305 -24.3%  
Net Cashflow Rs m-1,535-8,442 18.2%  

Share Holding

Indian Promoters % 32.3 63.7 50.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 5.1 89.7%  
FIIs % 3.3 23.0 14.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 8.3 666.3%  
Shareholders   84,811 133,026 63.8%  
Pledged promoter(s) holding % 54.9 0.5 10,362.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Economic Growth and Stock Markets: It's Not All Gloom and Doom(Podcast)

In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

How We Made 12.68% in One Overnight Trade(The 5 Minute Wrapup)

Nov 25, 2019

This one trade had my subscribers laughing all the way to the bank.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

Two Trends to Look at as Sensex Crosses 41,000 Levels(Views On News)

Nov 26, 2019

The two trends that are playing out as Sensex touches new record high.

The Best Trading Strategy for Fast Profits

Nov 29, 2019

Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - STERLING BIOTECH COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS